Inside Stocks
Universe/Pharmaceutical Preparations/CTOR

Citius Oncology, Inc.

CTOR · US · USD
Watchlist and comparison: planned
Market value59.54 m USD
Industry per SECPharmaceutical Preparations
Price as of12 Oct 2026
Last financial year2025
Latest filing10-Q, 14 Aug 2026
Method version2.7.0
Years in the base4
Company quality, four grades from 0 to 5
Balance sheet3
Profitability0
Cash flow1
Growth—
Total points— of 20
Share valuation, scored separately

No reliable range can be derived for this company. The reason is given below.

The key figures

free to read

All values from audited annual reports filed with the US regulator SEC. No value is estimated, none smoothed.

GradePointsBasis
Balance sheet3/5not reported · Current ratio 0.6
How this grade is built
Net debt to operating incomenot reported5/51: ≤ 4.0×2: ≤ 3.0×3: ≤ 2.0×4: ≤ 1.0×5: ≤ 0.0×
Current ratio0.60/51: ≥ 0.82: ≥ 1.03: ≥ 1.34: ≥ 1.85: ≥ 2.5Next step: at least 0.8 for grade 1
Mean 5 + 0 / 2 = 2.50, rounded 3
Profitability0/5Operating margin not reported · Return on equity -55.2%
How this grade is built
Operating marginnot reported—1: ≥ 0.0%2: ≥ 5.0%3: ≥ 12.0%4: ≥ 20.0%5: ≥ 30.0%
Return on equity-55.2%0/51: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%Next step: at least 0.0% for grade 1
Mean 0 / 1 = 0.00, rounded 0
Cash flow1/5Free cash flow to revenue not reported · Profit covered by cash flow not reported · Free cash flow positive 1 of 4 years
How this grade is built
Free cash flow to revenuenot reported—1: ≥ 0.0%2: ≥ 5.0%3: ≥ 10.0%4: ≥ 18.0%5: ≥ 25.0%
Profit covered by cash flownot reported—1: ≥ 0.4×2: ≥ 0.6×3: ≥ 0.8×4: ≥ 1.0×5: ≥ 1.2×
Free cash flow positive1 of 4 years1/51: 1 of 42: 2 of 43: 2 of 44: 3 of 45: 4 of 4Next step: at least 2/5 for grade 2
Mean 1 / 1 = 1.00, rounded 1
Growth—No grade, because data is missing. It is not estimated.
How this grade is built
Revenue growth per yearnot reported—1: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%
Operating income per yearnot reported—1: ≥ 0.0%2: ≥ 3.0%3: ≥ 8.0%4: ≥ 15.0%5: ≥ 25.0%
No component could be calculated, so there is no grade.

Each grade is the rounded mean of two or three key figures, each placed on a five-step scale. Open the derivation under a grade to see, for every figure, the measured value, the step it reached and what the next step would have required.

The valuation range

free to read

No range is reported for this company. Not enough history.

Within the sector

free to read

Median of total points in this industry: 10.0 of 20, across 152 graded companies. The grades are absolute and are not normalised to the sector: in a weak industry a weak grade stays weak.

The neighbours follow from the ranking alone, not from a judgement. More total points does not mean a company is the better investment, only that more quality rules are met. It says nothing about the price.

The series of figures

free to read

Every figure comes from the annual report of that year and has not been revised afterwards. Amounts in USD.

Swipe sideways for all columns.

YearRevenueOperating profitFree cash flowEarnings per shareSharesNet debt
2022—-138.12 k-47.97 k0.026.71 m—
2023—-1.01 m-601.30 k0.276.60 m—
2024—-20.57 m126.35 k-0.3168.05 m-112
2025—-23.52 m-5.49 m-0.3473.27 m-3.92 m

Next figures

Expected on 22 Dec 2026 (estimated from the rhythm of earlier filings, ± 21 days). Grades can change after a report; the page is then rebuilt.

Required disclosures for this analysis

Produced byFlorian Maier
Completed on14.10.2026 03:58
Price as of12 Oct 2026
Latest filing10-Q, 14 Aug 2026
Method version2.7.0
Time horizonThe grades describe a state that can change with every annual report, so roughly quarterly. The historical analysis is computed over 36 months.
Own positionNot disclosed individually, see the risk notice.
Earlier analysesThe list of all analyses of this company from the past twelve months will appear once twelve months of analyses exist. This run is the start of the series.

This is not investment advice. Limits of the method, assumptions and conflicts of interest: risk notice.